Discriminative stimulus properties of intragastrically administered d-amphetamine and pentobarbital in rhesus monkeys.
Rhesus monkeys were trained to discriminate intragastrically administered d-amphetamine (AMPH) or pentobarbital (PENTO) from saline using a signaled shock-avoidance trail procedure. All monkeys maintained criterion levels (greater than 90% drug-appropriate responding) throughout the duration of the study during training sessions. In the AMPH experiment, the anorectics diethylpropion, mazindol, phendimetrazine, phenmetrazine and phentermine completely substituted for the training dose of AMPH. The atypical antidepressant bupropion and the psychomotor stimulant methylphenidate also completely substituted for AMPH. Other anorectics including benzphetamine, clortermine, fenetylline, mefenorex and the psychomotor stimulant pemoline that share some pharmacological properties with AMPH substituted for AMPH in some, but not all, of the monkeys tested. The anorectics fenfluramine and chlorphentermine failed to substitute for AMPH. Drugs from other pharmacological classes such as morphine, diazepam, nortripyline and PENTO also failed to substitute for AMPH, indicating pharmacological specificity. In the PENTO experiment, the benzodiazepines alprazolam, bromazepam, diazepam, flurazepam, halazepam, lorazepam, midazolam, oxazepam, temazepam and triazolam and the sedatives methaqualone and phenobarbital completely substituted for the training dose of PENTO. The nonbenzodiazepine anxiolytic CL 218,872 only partially substituted for PENTO. In addition, morphine and AMPH failed to substitute for PENTO, indicating pharmacological specificity. In summary, drugs delivered intragastrically functioned as discriminative stimuli in a drug-class specific manner. The ability to use drugs delivered by this route as discriminative stimuli provides a way to compare anorectic drugs to AMPH or sedative drugs to PENTO under conditions that resemble the mode of human consumption to determine whether these drugs are likely to be associated with AMPH-like or PENTO-like drug dependence.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001067:Appetite Depressants / Q000494:pharmacology; D016642:Bupropion; D003913:Dextroamphetamine / Q000494:pharmacology*; D004193:Discrimination Learning / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D008253:Macaca mulatta; D008297:Male; D009020:Morphine / Q000494:pharmacology; D009661:Nortriptyline / Q000494:pharmacology; D010424:Pentobarbital / Q000494:pharmacology*; D011427:Propiophenones / Q000494:pharmacology; D019966:Substance-Related Disorders
D014151:Anti-Anxiety Agents; D001067:Appetite Depressants; D011427:Propiophenones; D016642:Bupropion; D009020:Morphine; D009661:Nortriptyline; D010424:Pentobarbital; D003913:Dextroamphetamine